Genmab — Juni 2017
-
Apropos opdateret Pollux har dette vist ikke været nævnt her: In patients with standard cytogenetic risk (…) the daratumumab combination regimen resulted in an ORR of 95% vs. 82% (p=0.0004), with VGPR or better achieved in 85% vs. 55% of patients, and CR or better achieved in 58% vs. 27% of patients treated with DRd vs. Rd
-
I high risk ser Castor næsten lige så godt ud som Pollux: https://www.advfn.com/news_Darzalex-daratumumab-Combination-Therapy-Improve_74919916.html
-
-
Vi ser vist nogle investorer som er på "sell on facts" i dag. Det var forventeligt.
-
-
ja det var som forventet. Salgstal måned for måned er en spændende kurstrigger. Der skulle gerne være flot vækst i receptudskrivelserne i takt med, at Jansen giver fuld speed på ulrulningen.
-
Men ja resultater uden for MM er yderst interessant at følge.
-
Selvom der er forventet mega mega blockbuster i Darzalex, så er Genmab virkelig blevet et interessant selskab, da det er imponerende skabe et sådan produkt.
-
-
enig jkj.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind